RLYB vs. DERM, ANEB, SLS, LABP, CRVS, SPRO, CNTB, ASMB, TPST, and ALRN
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Journey Medical (DERM), Anebulo Pharmaceuticals (ANEB), SELLAS Life Sciences Group (SLS), Landos Biopharma (LABP), Corvus Pharmaceuticals (CRVS), Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Assembly Biosciences (ASMB), Tempest Therapeutics (TPST), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical preparations" industry.
Rallybio (NASDAQ:RLYB) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Rallybio has a net margin of 0.00% compared to Journey Medical's net margin of -4.87%. Journey Medical's return on equity of -34.08% beat Rallybio's return on equity.
In the previous week, Journey Medical had 1 more articles in the media than Rallybio. MarketBeat recorded 2 mentions for Journey Medical and 1 mentions for Rallybio. Journey Medical's average media sentiment score of 0.13 beat Rallybio's score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.
Journey Medical has higher revenue and earnings than Rallybio. Journey Medical is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
Rallybio currently has a consensus price target of $12.20, suggesting a potential upside of 535.42%. Journey Medical has a consensus price target of $8.50, suggesting a potential upside of 147.09%. Given Rallybio's higher possible upside, equities research analysts clearly believe Rallybio is more favorable than Journey Medical.
90.3% of Rallybio shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 7.4% of Rallybio shares are owned by company insiders. Comparatively, 19.4% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Rallybio received 31 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 74.42% of users gave Rallybio an outperform vote.
Rallybio has a beta of -1.63, indicating that its share price is 263% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Summary
Journey Medical beats Rallybio on 11 of the 17 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
